hematolog
virolog
effect
recombin
human
granulocyt
colonystimul
factor
rhugcsf
evalu
felin
immunodefici
viru
fiv
infect
cat
six
agematch
fivinfect
cat
use
crossov
studi
inject
subcutan
mg
hematopoiet
growth
factor
regul
growth
develop
function
hematopoiet
lineag
use
immun
reconstitut
therapi
human
anim
clinic
relev
hematopoiet
growth
factor
veterinari
medicin
erythropoietin
epo
granulocyt
colonystimul
factor
gcsf
granulocytemacrophag
colonystimul
factor
gmcsf
ogilvi
sinc
speciesspecif
growth
factor
commerci
unavail
veterinari
medicin
recombin
human
growth
factor
fdaapprov
human
use
use
anim
ogilvi
recombin
human
epo
rhuepo
enhanc
red
blood
cell
product
use
veterinari
medicin
therapi
anemia
result
chronic
renal
failur
cancer
chemotherapi
reduc
need
transfus
surgeri
ogilvi
similar
use
human
recombin
human
gcsf
rhugcsf
gmcsf
rhugmcsf
use
increas
product
function
activ
neutrophil
monocyt
anim
infecti
diseas
chemotherapyinduc
myelosuppress
ogilvi
howev
drug
veterinarylabel
product
potenti
risk
must
consid
relat
therapeut
benefit
veterinari
use
foremost
potenti
advers
reaction
caus
develop
antibodi
human
product
may
limit
factor
longterm
use
felin
immunodefici
viru
fiv
lentiviru
caus
immunodefici
syndrom
domest
cat
pedersen
et
al
yamamoto
et
al
hematolog
abnorm
anemia
neutropenia
lymphopenia
typic
manifest
fiv
infect
cat
henc
use
hematopoiet
growth
factor
greatli
benefit
fivinfect
cat
improv
qualiti
life
find
shortterm
studi
alreadi
report
use
rhuepo
rhugmcsf
support
therapi
fivinfect
cat
arai
et
al
studi
demonstr
rhuepo
could
use
safe
fivinfect
cat
increas
rbc
count
without
chang
fiv
statu
develop
antirhuepo
antibodi
compar
rhuepo
efficaci
rhugmcsf
remark
low
result
increas
neutrophil
monocyt
treat
cat
product
antirhugmcsf
antibodi
increas
fiv
load
arai
et
al
result
use
rhugmcsf
recommend
fivinfect
cat
requir
altern
drug
identifi
treat
neutropenia
anim
like
fivinfect
cat
neutropenia
wellknown
clinic
outcom
hiv
infect
human
yamamoto
et
al
coyl
common
side
effect
antifiv
antihiv
therapi
coyl
arai
et
al
arai
et
al
help
counter
loss
neutrophil
hivinfect
individu
treat
success
rhugcsf
coyl
aladdin
et
al
howev
studi
report
date
efficaci
rhugcsf
treatment
fivinfect
cat
unlik
gmcsf
regul
develop
earlier
uncommit
progenitor
cell
stem
cell
multipot
progenitor
gcsf
stimul
predominantli
prolifer
differenti
activ
commit
neutrophilgranulocyt
progenitor
function
matur
neutrophil
hollingshead
goa
paper
report
hematolog
virolog
effect
rhugcsf
treatment
fivinfect
cat
vitro
h
thymidin
incorpor
assay
perform
assess
effect
rhugcsf
prolifer
pbmc
bm
cell
primari
pbmc
bm
cell
specif
pathogenfre
spf
cat
purifi
cellgro
lymphocyt
separ
medium
mediatech
inc
herndon
va
yamamoto
et
al
cultur
triplic
ml
per
well
bm
ml
per
well
day
assay
media
supplement
vari
concentr
ngml
rhugcsf
neupogen
filgrastim
amgen
inc
thousand
oak
ca
assay
media
consist
rpmi
media
contain
heatinactiv
fc
mm
hepe
mgml
gentamycin
h
thymidin
ad
h
prior
cell
harvest
day
level
h
thymidin
incorpor
determin
liquid
scintil
analysi
present
cpm
per
cultur
effect
rhugcsf
fiv
replic
determin
tcellenrich
pbmc
primari
pbmc
bm
cell
tcellenrich
pbmc
deriv
stimul
pbmc
tcell
mitogen
cona
day
cultur
cell
addit
week
cultur
media
cultur
media
assay
media
prolifer
except
heatinactiv
fc
addit
uml
recombin
human
tcellenrich
pbmc
inocul
fiv
tissu
cultur
median
infecti
dose
tcid
cultur
week
cultur
media
supplement
set
concentr
rhugcsf
ngml
cultur
supernat
collect
everi
day
cell
resuspend
fresh
cultur
media
contain
appropri
concentr
rhugcsf
supernat
test
fiv
titer
revers
transcriptas
rt
assay
previous
describ
rey
et
al
studi
primari
pbmc
bm
cell
fivinfect
cat
cocultur
uninfect
tcellenrich
pbmc
week
cultur
medium
supplement
set
concentr
rhugcsf
tcellenrich
pbmc
tcell
base
phenotyp
analysi
pant
antibodi
yamamoto
et
al
primari
pbmc
neutrophil
contamin
wherea
tcellenrich
pbmc
detect
neutrophil
base
microscopi
wrightstain
supernat
collect
rt
assay
describ
cat
bred
laboratori
compar
immunolog
retrovirolog
lcir
hous
anim
care
facil
univers
florida
six
spf
cat
week
age
unrel
cat
vitro
studi
section
inocul
cat
median
infecti
dose
cid
fiv
chronic
infect
month
prior
initi
studi
upon
confirm
fiv
infect
cat
use
crossov
studi
consist
two
treatment
separ
rest
period
initi
studi
part
three
experiment
cat
receiv
mgkg
sc
inject
rhugcsf
neupogen
filgrastim
daili
week
three
control
cat
receiv
equival
volum
sc
salin
placebo
follow
rest
period
cat
group
revers
studi
part
studi
repeat
use
establish
treatment
regimen
approxim
month
complet
crossov
studi
three
cat
retreat
sc
day
week
mgkg
rhugcsf
cat
monitor
daili
clinic
sign
includ
loss
appetit
ocularnas
discharg
rectal
temperatur
bodi
weight
taken
sever
time
cours
studi
blood
drawn
twice
treatment
everi
day
treatment
three
time
treatment
complet
blood
count
cbc
blood
chemistri
phenotyp
yamamoto
et
al
fiv
load
analysi
pbmc
yamamoto
et
al
antifiv
antibodi
titrat
yamamoto
et
al
antigcsf
antibodi
analys
cat
retreat
studi
monitor
cbc
antigcsf
antibodi
retreat
period
bone
marrow
cell
cat
evalu
myeloid
erythroid
e
ratio
start
treatment
treatment
follow
end
treatment
bone
marrow
aspir
ml
collect
femur
prepar
ml
edta
solut
bm
smear
slide
previous
describ
freeman
submit
clinic
patholog
laboratori
colleg
veterinari
medicin
univers
florida
analysi
recombin
fegcsf
produc
use
vector
escherichia
coli
origami
tm
placi
strain
recommend
manufactur
novagen
emd
bioscienc
inc
san
diego
ca
express
product
purifi
use
macroprep
high
biogel
htp
hydroxyapatit
chromatographi
biorad
inc
hercul
ca
puriti
rfegcsf
base
silver
stain
analysi
antirhugcsf
antirfegcsf
antibodi
level
determin
elisa
recombin
hugcsf
rfegcsf
coat
plate
ngwell
block
wash
plate
incub
serial
dilut
serum
triplic
h
remain
procedur
elisa
previous
describ
yamamoto
et
al
except
use
mgml
azinodi
sulfon
acid
h
elisa
substrat
solut
sera
rhugcsftreat
cat
test
neutral
antibodi
rhugcsf
rfegcsf
use
neutral
assay
base
prolifer
gcsfsensit
cell
weinstein
et
al
shirafuji
et
al
ml
serial
dilut
sera
mix
ml
eight
efficaci
dose
ed
either
rhugcsf
rfegcsf
incub
h
ed
rhugcsf
rfegcsf
ngml
respect
initi
incub
ml
suspens
sampl
ad
duplic
well
contain
ml
cell
subsequ
incub
addit
h
cell
prolifer
measur
celltit
aq
ueou
one
solut
cell
prolifer
assay
promega
corp
madison
wi
repres
result
three
separ
assay
shown
dilut
titer
provid
inhibit
compar
valu
cellprolifer
pretreat
sera
result
vitro
studi
analyz
statist
signific
use
student
ttest
cat
divid
treatment
versu
placebo
group
ttest
analysi
e
ratio
fiv
load
antifiv
antibodi
titer
confid
interv
analysi
use
evalu
hematolog
result
vivo
studi
confid
interv
use
compar
follow
group
rhugcsftreat
cat
sampl
versu
control
cat
sampl
pretreat
versu
treatment
sampl
pretreat
versu
posttreat
sampl
treatment
versu
posttreat
sampl
group
consid
statist
differ
base
confid
interv
ci
analyz
ttest
final
statist
comparison
pvalu
less
consid
statist
signific
vitro
studi
perform
evalu
direct
effect
rhugcsf
prolifer
felin
pbmc
bm
cell
determin
effect
rhugcsf
fiv
replic
felin
pbmc
bm
cell
primari
pbmc
two
four
spf
cat
slight
irregular
nondosedepend
increas
prolifer
respons
vari
concentr
rhugcsf
fig
part
contrast
slight
consist
dosedepend
increas
prolifer
respons
observ
bm
cell
four
spf
cat
fig
part
howev
increas
bm
prolifer
statist
signific
consequ
pbmc
bm
cell
fivinfect
cat
test
prolifer
respons
rhugcsf
use
determin
vitro
effect
rhugcsf
treatment
fiv
replic
none
pbmc
bm
cell
cultur
vitroli
infect
tcellenrich
pbmc
pbmc
bm
cell
fivinfect
cat
increas
fiv
replic
due
rhugcsf
treatment
fig
part
henc
vitro
result
demonstr
rhugcsf
direct
effect
fiv
replic
pbmc
bm
cell
even
though
slight
prolifer
uninfect
bm
cell
occur
respons
rhugcsf
stimul
six
spf
cat
singl
litter
inocul
highli
virul
fiv
strain
five
six
cat
develop
fever
prior
studi
start
week
postinocul
extens
treat
antibiot
fluid
therapi
temperatur
return
normal
week
postsupport
therapi
except
cat
remain
cat
clinic
healthi
afebril
receiv
drug
therapi
start
studi
cat
treat
prednisolon
mg
oral
day
throughout
part
studi
control
recurr
fever
caus
potenti
fiv
infect
except
day
placebo
treatment
studi
part
throughout
retreat
studi
start
day
studi
part
two
cat
develop
mild
reaction
rhugcsf
treatment
studi
part
cat
develop
fever
red
inject
site
limp
right
forefoot
start
day
rhugcsf
treatment
clinic
sign
resolv
treatment
day
studi
part
cat
develop
appear
sensit
inject
may
instead
gener
resist
inject
red
swell
site
inject
part
studi
hematolog
find
within
normal
limit
cat
suggest
rhugcsfinduc
drug
toxic
occur
although
blood
chemistri
valu
sever
cat
outsid
normal
rang
treatment
period
baselin
valu
outsid
normal
rang
cat
prior
treatment
suggest
abnorm
valu
like
due
fiv
infect
except
cat
five
six
rhugcsftreat
cat
signific
increas
averag
wbc
count
treatment
compar
baselin
fig
cat
exhibit
elev
wbc
count
least
neutrophilsml
increas
baselin
valu
peak
treatment
day
moreov
wbc
count
six
rhugcsftreat
cat
statist
higher
placebo
group
treatment
day
fig
b
addit
rhugcsftreat
group
significantli
higher
averag
wbc
count
treatment
day
averag
baselin
day
wbc
count
neutrophil
count
rhugcsftreat
group
show
similar
trend
observ
wbc
count
cours
studi
fig
five
rhugcsftreat
cat
statist
signific
increas
wbc
count
fig
wbc
neutrophil
lymphocyt
eosinophil
monocyt
count
fivinfect
cat
undergo
rhugcsf
treatment
arrow
bar
repres
time
treatment
day
statist
signific
differ
demonstr
rhugcsf
treatment
group
placebo
group
time
point
shown
posttreat
pretreat
valu
rhugcsf
treatment
group
shown
statist
signific
differ
establish
comparison
treat
group
vs
placebo
group
posttreat
vs
pretreat
shown
also
signific
increas
neutrophil
count
ie
least
neutrophilsml
increas
statist
signific
increas
averag
neutrophil
count
rhugcsftreat
versu
placebo
group
observ
treatment
day
fig
similar
wbc
count
averag
neutrophil
count
significantli
higher
rhugcsftreat
group
treatment
day
compar
averag
baselin
day
count
contrast
wbc
neutrophil
count
remain
rel
stabl
placebo
group
except
cat
part
treatment
day
fig
describ
cat
receiv
prednisolon
throughout
part
except
placebo
treatment
day
coincid
increas
wbc
neutrophil
count
treatment
day
howev
part
increas
wbc
count
cat
rhugcsf
treatment
affect
prednisolon
given
cat
throughout
studi
statist
signific
increas
lymphocyt
count
observ
rhugcsftreat
cat
compar
placebo
control
compar
baselin
pretreat
valu
day
fig
f
eosinophil
count
highli
variabl
treatment
group
although
significantli
differ
compar
either
baselin
pretreat
valu
day
placebo
group
except
treatment
day
fig
h
although
monocyt
count
highli
variabl
cat
appear
pronounc
elev
monocyt
count
rhugcsftreat
cat
compar
placebo
control
fig
j
howev
statist
signific
increas
monocyt
count
observ
rhugcsftreat
group
compar
either
placebo
control
baselin
valu
day
furthermor
monocyt
count
placebotr
group
signific
increas
throughout
studi
hematolog
paramet
rbc
hemoglobin
platelet
hematocrit
affect
rhugcsf
treatment
data
shown
fivinfect
cat
low
e
ratio
rhugcsf
administr
tabl
compar
pretreat
baselin
day
valu
statist
signific
increas
e
ratio
rhugcsftreat
cat
observ
week
treatment
day
tabl
week
cessat
treatment
day
increas
averag
e
ratio
consist
pronounc
rhugcsftreat
group
result
statist
signific
e
ratio
compar
placebo
group
treatment
day
addit
baselin
valu
treatment
day
posttreat
day
although
slight
transient
e
ratio
increas
observ
two
placebotr
cat
placebotr
cat
individu
group
exhibit
statist
signific
increas
e
ratio
tabl
henc
signific
e
ratio
observ
rhugcsftreat
group
fluctuat
fiv
load
observ
pbmc
rhugcsftreat
placebotr
cat
tabl
statist
signific
result
moreov
cat
maintain
rel
constant
antifiv
antibodi
titer
tabl
count
averag
cellsml
rang
cell
ratio
averag
rang
throughout
studi
result
taken
togeth
demonstr
rhugcsf
treatment
advers
effect
fiv
load
diseas
treat
anim
except
one
cat
five
six
cat
develop
antibodi
rhugcsf
day
posttreat
tabl
peak
antirhugcsf
antibodi
titer
detect
treatment
day
rang
titer
four
five
cat
maintain
detect
antirhugcsf
antibodi
titer
long
week
withdraw
treatment
day
tabl
antirhugcsf
antibodi
two
cat
highest
titer
antibodi
also
crossreact
rfegcsf
elisa
tabl
four
six
cat
elisa
neutral
antibodi
titer
rhugcsf
tabl
fig
addit
two
cat
elisa
antibodi
titer
rfegcsf
detect
neutral
antibodi
rfegcsf
treatment
posttreat
day
neutral
antibodi
either
rhugcsf
rfegcsf
detect
pretreat
sera
approxim
month
withdraw
rhugcsf
treatment
three
cat
retreat
week
daili
rhugcsf
dose
previous
describ
abil
sera
neutral
rhugcsf
rfegcsf
test
three
cat
develop
signific
level
neutral
antibodi
rhugcsf
week
retreat
fig
e
f
addit
cat
b
statist
signific
differ
exist
preand
posttreat
valu
rhugcsf
treatment
group
denot
also
rhugcsf
treatment
group
placebo
groupdenot
mean
sd
b
ae
ae
ae
ae
ae
ae
ae
ae
number
day
postfirst
treatment
b
statist
signific
differ
observ
pretreat
posttreat
treatment
placebo
group
develop
low
neutral
antibodi
titer
rfegcsf
week
retreat
fig
sinc
observ
first
report
case
crossneutr
antibodi
fegcsf
result
confirm
perform
three
addit
assay
result
confirm
find
overal
studi
suggest
repeat
cycl
rhugcsf
treatment
lead
induct
neutral
antibodi
hugcsf
potenti
fegcsf
fivinfect
cat
known
multilineag
hematopoiet
defect
lymphopenia
neutropenia
anemia
shelton
et
al
fleme
et
al
spark
et
al
previou
studi
treat
fivinfect
cat
rhugmcsf
instead
rhugcsf
multilineag
activ
gmcsf
could
use
immun
reconstitut
fivinfect
cat
arai
et
al
howev
rhugmcsftreat
cat
respond
treatment
increas
neutrophil
eosinophil
lymphocyt
monocyt
rbc
combin
addit
increas
multipl
popul
hematocyt
fivinfect
cat
concomit
log
increas
fiv
load
observ
rhugmcsf
treatment
unlik
rhugmcsf
studi
current
rhugcsf
studi
clearli
demonstr
fiv
load
increas
rhugcsf
treatment
cat
suggest
drug
select
neutrophil
monocyt
fact
pronounc
statist
signific
increas
neutrophil
count
observ
rhugcsf
treatment
fig
compar
slight
irregular
increas
monocyt
count
statist
signific
fig
j
moreov
rhugmcsf
signific
effect
fiv
load
peripher
blood
wherea
rhugcsf
sinc
fiv
product
infect
monocytesmacrophag
neutrophil
kube
et
al
observ
demonstr
import
neutrophil
count
increas
compar
slight
irregular
monocyt
increas
unlik
rhugmcsf
rhugcsf
increas
vitro
fiv
replic
monocytecontain
pbmc
bm
cell
fivinfect
cat
fig
part
gcsf
function
growth
factor
neutrophil
progenitor
induc
prolifer
differenti
myeloid
cell
neutrophil
frampton
et
al
howev
matur
neutrophil
affect
differenti
function
prolifer
frampton
et
al
consequ
current
studi
evalu
effect
rhugcsf
treatment
myeloid
cell
measur
e
ratio
tabl
product
antirhugcsf
antirfegcsf
antibodi
rhugcsftreat
cat
studi
part
cat
elisa
antigcsf
antibodi
titer
b
neutral
antibodi
titer
b
placebotr
cat
antigcsf
antibodi
except
cat
cat
elisa
antibodi
rhugcsf
rfegcsf
remain
studi
part
time
placebo
treatment
studi
part
cat
residu
antirhugcsf
antibodi
time
placebo
treatment
studi
part
result
rhugcsftreat
cat
shown
b
antibodi
titer
rhugcsf
shown
follow
titer
rfegcsf
parenthesi
symbol
u
repres
undetect
antirhugcsf
antirfegcsf
antibodi
lowest
serum
dilut
elisa
neutral
antibodi
assay
symbol
u
repres
undetect
antirfegcsf
antibodi
monitor
progenitor
neutrophil
prolifer
recombin
hugcsf
treatment
fivinfect
cat
significantli
increas
e
ratio
along
concomit
increas
neutrophil
count
blood
observ
import
fiv
especi
fiv
report
infect
bm
cell
caus
hematolog
abnorm
marrow
week
postfiv
inocul
tanab
yamamoto
fig
neutrophil
product
kinet
neutral
antibodi
titer
individu
cat
treat
rhugcsf
sera
pretreat
day
treatment
day
posttreat
day
test
neutral
antibodi
titer
sera
undetect
neutral
antibodi
titer
shown
n
cat
panel
c
panel
e
panel
f
retreat
rhugcsf
day
sera
test
neutral
antibodi
titer
rhugcsf
rfegcsf
day
retreat
thick
grey
line
solid
symbol
repres
neutrophil
count
rhugcsf
treatment
three
cat
develop
signific
neutral
antibodi
titer
rhugcsf
cat
neutral
antibodi
rfegcsf
day
retreat
compar
report
increas
e
ratio
neutrophil
count
fivfre
cat
undergo
gcsf
treatment
phillip
current
result
indic
fiv
infect
statu
significantli
affect
abil
bm
cell
respond
rhugcsf
treatment
neutrophil
count
major
rhugcsftreat
fivinfect
cat
peak
treatment
day
steadili
declin
thereaft
sinc
cat
continu
treat
daili
week
includ
day
moder
rapid
declin
neutrophil
count
treatment
suggest
potenti
develop
neutral
antibodi
rhugcsf
two
cat
exhibit
declin
neutrophil
count
baselin
level
treatment
day
develop
highest
titer
elisa
antirhugcsf
antibodi
along
antirhugcsf
neutral
antibodi
product
day
treatment
fig
e
tabl
observ
neutrophil
product
kinet
correspond
neutral
antibodi
product
cat
similar
neutrophil
product
kinet
antirhugcsf
antibodi
titer
report
dog
lothrop
et
al
result
repres
first
report
antirhugcsf
elisa
neutral
antibodi
product
fivinfect
cat
undergo
rhugcsf
treatment
three
cat
develop
antirhugcsf
neutral
antibodi
titer
first
week
treatment
retreat
rhugcsf
day
determin
whether
neutral
antibodi
develop
would
reoccur
month
without
supplement
treatment
fig
e
f
three
cat
minim
detect
antirhugcsf
neutral
antibodi
titer
begin
retreat
period
titer
two
cat
significantli
increas
retreat
day
fig
e
correspond
antibodi
increas
slight
increas
neutrophil
count
retreat
day
follow
sharp
decreas
neutrophil
number
retreat
day
return
near
baselin
titer
contrast
cat
absenc
prednisolon
therapi
respond
rhugcsf
retreat
sharp
neutrophil
increas
retreat
day
continu
day
despit
develop
antirhugcsf
neutral
antibodi
fig
three
week
postretreat
studi
cat
develop
high
fever
underw
highdos
prednisolon
therapi
euthan
shortli
thereaft
time
euthanasia
cat
proteinuria
gdl
felin
infecti
periton
fip
coronaviru
titer
histopatholog
reveal
uncharacterist
fiprel
intestin
lesion
harvey
et
al
thu
neutrophil
increas
cat
retreat
studi
may
caus
fipassoci
neutrophilia
hoskin
wherea
two
cat
without
prednisolon
respond
retreat
decreas
neutrophil
count
upon
develop
high
antirhugcsf
neutral
antibodi
titer
even
though
retrospect
studi
retreat
sera
demonstr
fipcoronaviru
titer
cat
cat
retrospect
sudden
increas
neutrophil
count
day
placebo
treatment
studi
part
cat
may
result
fipinduc
neutrophilia
sinc
coincid
prednisolon
withdraw
concomit
transient
increas
fipcoronaviru
titer
fig
even
prednisolon
treatment
cat
abl
respond
rhugcsf
treatment
studi
part
neutrophil
increas
transient
twofold
increas
fipcoronaviru
antibodi
titer
sign
fip
diseas
result
suggest
rhugcsf
treatment
combin
prednisolon
therapi
safe
elev
neutrophil
count
e
ratio
fiv
fip
coinfect
cat
without
caus
clinic
ill
fig
tabl
moreov
cat
hous
quarter
includ
cat
detect
titer
fip
coronaviru
exhibit
clinic
fip
sign
part
studi
henc
rhugcsf
treatment
result
period
affect
ongo
fip
infect
cat
recombin
hugcsf
differ
fegcsf
amino
acid
aa
ident
yamamoto
unpublish
data
consequ
least
rhugcsf
foreign
felin
immun
system
foreign
epitop
potenti
stimul
felin
lymphocyt
may
enhanc
replic
fiv
addit
rhugmcsf
differ
fegmcsf
aa
ident
report
increas
fiv
replic
primari
felin
pbmc
tcellenrich
pbmc
cultur
arai
et
al
unlik
rhugmcsf
studi
demonstr
rhugcsf
use
fivinfect
cat
increas
neutrophil
count
without
enhanc
fiv
infect
howev
rhugcsf
neutral
antibodi
develop
earli
day
treatment
sinc
rhugcsf
aa
sequenc
foreign
felin
immun
system
moreov
longterm
use
repeat
cycl
treatment
may
result
product
neutral
antibodi
hugcsf
includ
crossneutr
antibodi
endogen
fegcsf
similar
studi
effect
recombin
canin
gcsf
rcagcsf
treatment
cat
show
lack
neutrophil
declin
beyond
day
treatment
rcagcsf
suggest
product
neutral
antibodi
rcagcsf
colgan
et
al
obradovich
et
al
sinc
gcsf
cat
dog
differ
aa
ident
potenti
develop
neutral
antibodi
rcagcsf
cat
concern
use
rfegcsf
prefer
recent
shortterm
rfegcsf
studi
suggest
treatment
cat
rfegcsf
better
treatment
option
either
rhugcsf
rcagcsf
yamamoto
et
al
unpublish
observ
treatment
studi
high
daili
dose
mgdose
rfegcsf
demonstr
rapid
increas
neutrophil
count
sign
antirfegcsf
antibodi
product
base
sole
neutrophil
kinet
time
drug
withdraw
yamamoto
et
al
unpublish
observ
howev
studi
suggest
day
treatment
may
short
observ
antibodi
rfegcsf
sinc
product
homolog
aa
sequenc
endogen
fegcsf
accord
publish
report
antibodi
product
homolog
growth
factor
human
subject
treat
rhugcsf
develop
elisabas
antibodi
without
develop
neutral
antibodi
rhugcsf
amgen
inc
like
rhugcsf
treatment
hivinfect
individu
longterm
recurr
treatment
rfegcsf
may
import
fivinfect
cat
suscept
recurr
bacteri
infect
due
immunodefici
state
pedersen
et
al
yamamoto
et
al
shelton
et
al
fleme
et
al
spark
et
al
commerci
develop
rfegcsf
infanc
cost
prohibit
due
difficulti
largescal
product
rfegcsf
low
yield
convent
express
system
e
coli
addit
rhugcsf
still
consid
cost
prohibit
longterm
use
felin
medicin
henc
futur
effort
place
cost
effect
commerci
develop
rfegcsf
use
effect
safe
cat
without
product
neutral
antibodi
block
drug
activ
